How Is Cyclopharm Driving Rapid US Expansion of Technegas® Lung Imaging?
Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.
- 50 revenue-generating Technegas® installations in the US
- New multi-site contracts with leading health systems including MUSC and Stony Brook
- Expansion within Veterans Affairs hospitals continues
- Clinical guidelines expected to endorse Technegas® as preferred ventilation imaging agent
- Engagement with approximately 25% of US nuclear medicine lung imaging sites
Cyclopharm's US Growth Momentum
Cyclopharm Limited (ASX:CYC) has announced a significant acceleration in the commercial rollout of its Technegas® lung imaging technology across the United States. Building on recent multi-site agreements, the company is expanding its footprint within major health systems and Veterans Affairs hospitals, marking a clear inflection point in its US strategy.
Recent contract wins include expansions at Mass General Brigham, with a second installation at Brigham and Women’s Hospital, and new installations at the University of North Carolina Health System and Emory Health Care. The company also secured a purchase order from the Joseph Maxwell Cleland Atlanta VA Medical Center, its fifth VA hospital adopting Technegas®, highlighting growing government sector engagement.
New Institutional Partnerships
Adding to its momentum, Cyclopharm signed new contracts with the Medical University of South Carolina (MUSC) and Stony Brook University Health System in New York. These agreements not only broaden Cyclopharm’s presence in key regional markets but also demonstrate the company’s success in penetrating high-quality academic and integrated healthcare networks.
As of 31 March 2026, Cyclopharm reports 50 revenue-generating installations in the US, linked to an additional 331 contracted locations. The pipeline includes dozens more sites in various stages of contracting and review, underscoring the scalability of its growth model.
Clinical Validation Boosts Adoption Prospects
Crucially, Cyclopharm is nearing a major clinical milestone with the anticipated finalisation of US and international ventilation-perfusion imaging guidelines. These guidelines are expected to formally recognise Technegas® as a preferred ventilation imaging agent, a development that could significantly influence physician practice, hospital procurement, and reimbursement decisions.
This clinical endorsement is poised to accelerate Technegas® adoption across the US healthcare landscape, complementing the company’s expanding commercial footprint and reinforcing its position in nuclear medicine lung imaging.
Strategic Outlook
Cyclopharm’s three-stage US expansion strategy; establishing lighthouse sites, building regional density, and expanding across integrated networks; is clearly gaining traction. With engagement now covering roughly a quarter of all US nuclear medicine lung imaging sites, the company is well positioned to capitalise on growing demand for advanced lung imaging solutions.
Bottom Line?
Cyclopharm’s US expansion is gathering pace, but the market will watch closely how clinical guideline finalisation translates into sustained revenue growth.
Questions in the middle?
- How quickly will contracted sites convert to revenue-generating installations?
- What impact will the final clinical guidelines have on reimbursement and hospital adoption?
- Can Cyclopharm sustain momentum in the competitive US nuclear medicine market?
